CasInvent Participates in Leukemia360 to Advance Collaboration in AML Research

CasInvent Pharma was pleased to take part in Leukemia360, an international meeting organized by the OPALE Carnot Institute in Paris. Our CEO, Dr. Alexander Scheer, and Head of Alliance, Tomáš Prát, represented the company at this event focused on shaping the future of leukemia research.

Leukemia360 brings together leading experts from academia and industry with the shared goal of accelerating innovation and improving outcomes for patients. The conference’s emphasis on translating scientific discoveries into real therapeutic benefit aligns closely with CasInvent’s mission to develop next-generation CK1 inhibitors, which hold strong potential in the treatment of acute myeloid leukemia (AML).

Throughout the meeting, our team engaged in conversations with researchers and potential partners dedicated to advancing new solutions for hematological malignancies. These interactions provided valuable opportunities to explore collaborative paths that could help bring future therapies closer to patients.

We thank the organizers and all collaborators for an inspiring event and look forward to continuing the discussions from Paris.